March 31, 2026
Adoption of recommendations to skip sentinel lymph node biopsy (SLNB) in older women with hormone-receptor (HR)-positive, HER2-negative early-stage breast cancer may be slowly gaining traction in […]
March 30, 2026
The European panel has expanded delivery options for multiple myeloma by approving a subcutaneous (SC) option for a key anti‑CD38 myeloma therapy. At its March 2026 […]
March 30, 2026
TOPLINE: Digital breast tomosynthesis (DBT) combined with digital mammography (DM) detected 50% more breast cancers at baseline compared with DM alone, showed no reduction in the […]
March 30, 2026
In a Mass General Brigham research lab, a team of scientists found such strong links between thymus health and longevity — and immunotherapy effectiveness — that […]
March 30, 2026
Patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer in Europe may soon have a new bladder-sparing treatment option after the European Medicines Agency’s Committee for […]
March 30, 2026
Katie Palay, who is in her 30s, has been in remission from Hodgkin lymphoma since 2010, but her cancer journey is far from over. A self-described […]
March 30, 2026
Subcutaneous administration of the anti-PD-1 monoclonal antibody toripalimab achieves similar drug exposure as the intravenous formulation in advanced non-squamous non-small cell lung cancer (NSCLC), with similar […]
March 30, 2026
MRI can identify patients with HER2-positive breast cancer who don’t need a full course of neoadjuvant chemotherapy, letting them avoid the toxicity of unnecessary treatment while […]
March 27, 2026
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two drugs for the treatment of adults with small […]